I undersøgelser med rekombinant faktor VIII præparater, er udvikling af inhibitorer overvejende set hos tidligere ubehandlede hæmofilipatienter.
In studies with recombinant factor VIII preparations, development of inhibitors is predominantly observed in previously untreated haemophiliacs.